BRKR Price Prediction Next Week
Analysis and Insights
News Sentiment and Recent Developments:
Dividend Announcement: Bruker declared a quarterly dividend of $0.05 per share, maintaining its yield at 0.38%. While this reflects stability, it may not significantly impact the stock price.
Q4 2024 Performance: Bruker reported strong revenue of $979.6 million, beating estimates by $13.99 million, and an EPS of $0.76, exceeding expectations by $0.02. The company projects 11%-13% EPS growth and margin expansion in 2025, driven by strong performance in the semiconductor and diagnostics sectors.
Full-Year 2024 Results: Despite a 14% revenue increase to $3.37 billion, net income fell 74% to $113.1 million, with a profit margin drop to 3.4%. High costs and expenses weighed on earnings.
Investor Activity: Michael Burry's hedge fund invested $7.3 million in Bruker, signaling some investor confidence.
Technical Analysis:
- RSI (14): 39.49, indicating oversold conditions and potential rebound.
- MACD: -2.22, showing bearish momentum.
- SMA: Trading below 20, 50, 60, 200, and 250-day moving averages, a bearish signal.
- Bollinger Bands: Near the lower band, suggesting undervaluation.
- Fibonacci Levels: Support at 44.27 (S1) and resistance at 51.61 (R1).
Price Prediction and Recommendation:
Based on the analysis, BRKR is expected to trade around $48.50 next week. The stock may experience a short-term rebound due to oversold conditions but could face resistance near $50.
Recommendation: Sell if the stock approaches $50, as technical indicators suggest limited upside potential.
BRKR Similar Chart Price Prediction
The price of BRKR is predicted to go up 0.72%, based on the high correlation periods with AAOI. The similarity of these two price pattern on the periods is 97.43%.
BRKR
AAOI
Up: 0.72%Similarity: 97.43%
BRKR Revenue Forecast
BRKR EPS Forecast
BRKR FAQs
What is BRKR revenue forecast for next quarter？
What is BRKR eps forecast for next quarter？
BRKR Analyst's Forecast
Luke Sergott
Barclays
Buy
2025-02-14
Price Target
$65 → $60
Upside
+20.31%
Barclays analyst Luke Sergott lowered the firm's price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm expects the life science tools and diagnostics group to be down today and sentiment to shift more negative following Friday's news around the Trump Administration's implementation of a 15% cap for National Institutes of Health reimbursement of "indirect costs" on the grants it awards universities. The news likely elevates concern on names like Bruker (BRKR), genomics Illumina (ILMN), 10x Genomics (TXG), and PacBio (PACB) and Thermo Fisher (TMO), Avantor (AVTR), Agilent (A), and Waters (WAT) to a lesser extent, the analyst tells investors in a research note.
Luke Sergott
Barclays
Buy
2025-02-10
Price Target
$69 → $65
Upside
+27.1%
Subbu Nambi
Guggenheim
Strong Buy
2024-12-19
Price Target
$72
Upside
+30.59%
